Vancouver, British Columbia – TheNewswire - June 27, 2025 – Pangea Natural Foods Inc. (CSE: PNGA) (OTC: PNGAF) (“Pangea” or the “Company”), a manufacturer and co-packer of health and wellness products, is pleased to provide a comprehensive corporate update as the company enters the second half of the year.

Headquartered in Vancouver, British Columbia, Pangea Natural Foods specializes in the development, production, and distribution of plant-based, non-GMO food products that are free from fillers, antibiotics, hormones, and bioengineered ingredients. Manufactured at a CFIA- and FDA-certified facility in Surrey, British Columbia, the Company’s flagship products include Plant-Based Patties, Old Fashioned Ghee, Energy Gel, and Munchie Mix. These products are available online and listed in over 500 retail outlets across North America, including Loblaws, Sobeys, Whole Foods, Save-On-Foods, and Choices Markets.

Acquisition of Amino Innovations Corp.

On April 9th, 2025, Pangea acquired 100% of the issued and outstanding shares of Amino Innovations Corp. (“Amino”), now operating as a wholly owned subsidiary of Pangea Natural Foods.

Amino Innovations is focused on delivering safe, needle-free peptide-based therapies designed to support everyday wellness. In contrast to traditional injectable peptide treatments, Amino’s formulations are delivered through convenient oral and topical delivery methods. These products aim to support recovery, cognition, longevity, inflammation reduction, stress management, hair and skin health, and immune function.

The company’s debut commercial product line includes seven flagship SKUs:

• CHILL – An oral capsule formulated with Dihydrohonokiol-B and Pinealon peptide to help reduce stress and support calm mental focus.  

• SKIN – A topical cream combining copper peptides and botanical hydrators to improve skin elasticity, smoothness, and hydration.  

• BPC – A high-absorption capsule containing BPC-157 to promote joint, muscle, and digestive recovery for active lifestyles.  

• KPV – A non-stimulant capsule containing Lysine-Proline-Valine peptide to support a balanced inflammatory response and healthy immune function. 

• AGELESS – An oral longevity formula combining NMN and Epitalon to support mitochondrial health, energy, and cognitive function. 

• BLUE – A cognitive support capsule with 25 mg of Methylene Blue to enhance mental clarity, focus, and sustained brain energy. 

• HAIR – A topical serum formulated with Copper Tripeptide-1 and Zinc Thymulin to nourish the scalp and support fuller, healthier hair growth. 

As of June 2025, all products are available to purchase online in the United States through its eCommerce platform at www.aminoinnovations.com.

The commercial launch of the Amino Innovations product line positions Pangea to capitalize on an expanding global market. “The global peptide supplements market size was valued at USD 2.67 billion in 2024 and is projected to reach USD 4.10 billion by 2032, with a CAGR of 5.5% during the forecast period of 2025 to 2032” (see: https://www.databridgemarketresearch.com/reports/global-peptide-supplements-market).

The Company looks forward to providing further updates to shareholders as it achieves key milestones. Amino is actively developing additional non-injectable formulations and expects to introduce a wellness patch prototype in Q3 2025.

 

About Pangea Natural Foods Inc.

 

Pangea Natural Foods Inc. is a North American manufacturer specializing in clean-label, plant-based foods and innovative wellness products. Through its subsidiary Amino Innovations, the Company offers advanced, needle-free peptide therapies that support recovery, cognitive function, and overall health.

 

On Behalf of the Board of Directors

"Pratap Sandhu"

Pratap Sandhu
CEO, Corporate Secretary and Director

+1 (604) 765-8069

Forward-Looking Information

This news release contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. More particularly and without limitation, this news release contains forward–looking statements and information relating Amino becoming the world’s first needleless peptide company and the expected benefits of the acquisition to the Company.  The forward–looking statements and information are based on certain key expectations and assumptions made by the management of the Company. As a result, there can be no assurance that the acquisition or related matters will be completed as proposed or at all. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward–looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward–looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the ability of the Company to complete its planned future activities and anticipated business plans. Other factors may also adversely affect the future results or performance of the Company, including general economic, market or business conditions, changes in the financial markets and changes in laws, regulations and policies affecting the Company's operations and the Company's limited operating history. Accordingly, readers should not place undue reliance on the forward–looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward– looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward–looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.